Compare OPAD & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAD | FEMY |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 37.2M |
| IPO Year | N/A | 2021 |
| Metric | OPAD | FEMY |
|---|---|---|
| Price | $0.79 | $0.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $1.83 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 1.1M | 407.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | $32.08 | $147.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $0.71 | $0.31 |
| 52 Week High | $6.35 | $1.76 |
| Indicator | OPAD | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 54.51 |
| Support Level | $0.71 | $0.54 |
| Resistance Level | $0.90 | $0.58 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 44.44 | 81.38 |
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.